IRAK1: A novel TOLLway to target ovarian cancer

被引：0
|
作者：
Standing, David [1 ]
Gunewardena, Sumedha [1 ]
Sayed, Afreen A. [1 ]
Pritchard, Michele T. [1 ]
Pathak, Harsh B. [1 ]
Godwin, Andrew K. [1 ]
Petersen, Shariska [1 ]
Khabele, Dineo [2 ]
Roy, Jensen A. [1 ]
Dandawate, Prasad [1 ]
Weir, Scott J. [1 ]
Anant, Shrikant [1 ]
机构：
[1] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
[2] Siteman Canc Ctr, St Louis, MO USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5306
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Inhibition of IRAK1 As a Novel Therapeutic Strategy in Acute Myeloid Leukemia and Myelodysplastic Syndrome
    Rhyasen, Garrett
    Bolanos, Lyndsey
    Fang, Jing
    Rigolino, Carmen
    Cortelezzi, Agostino
    Oliva, Esther Natalie
    Cuzzola, Mariella
    Starczynowski, Daniel T.
    BLOOD, 2011, 118 (21) : 281 - 281
  • [22] Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome
    Rhyasen, Garrett W.
    Bolanos, Lyndsey
    Fang, Jing
    Jerez, Andres
    Wunderlich, Mark
    Rigolino, Carmela
    Mathews, Lesley
    Ferrer, Marc
    Southall, Noel
    Guha, Rajarshi
    Keller, Jonathan
    Thomas, Craig
    Beverly, Levi J.
    Cortelezzi, Agostino
    Oliva, Esther N.
    Cuzzola, Maria
    Maciejewski, Jaroslaw P.
    Mulloy, James C.
    Starczynowski, Daniel T.
    CANCER CELL, 2013, 24 (01) : 90 - 104
  • [23] Multidimensional Mutational Profiling of the Indian HNSCC Sub-Population Provides IRAK1, a Novel Driver Gene and Potential Druggable Target
    Desai, Sagar Sanjiv
    Rao, Raksha K.
    Jain, Anika
    Bawa, Pushpinder Singh
    Dutta, Priyatam
    Atre, Gaurav
    Subhash, Anand
    Rao, Vishal U. S.
    Suvratha, J.
    Srinivasan, Subhashini
    Choudhary, Bibha
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [24] Recent Advances in IRAK1: Pharmacological and Therapeutic Aspects
    Kim, Kyeong Min
    Hwang, Na-Hee
    Hyun, Ja-Shil
    Shin, Dongyun
    MOLECULES, 2024, 29 (10):
  • [25] IRAK1: A critical signaling mediator of innate immunity
    Gottipati, Sridevi
    Rao, Navin L.
    Fung-Leung, Wai-Ping
    CELLULAR SIGNALLING, 2008, 20 (02) : 269 - 276
  • [26] Expression of IRAK1 in lung cancer tissues and its clinicopathological significance: a microarray study
    Zhang, Xiuling
    Dang, Yiwu
    Li, Ping
    Rong, Minhua
    Chen, Gang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2014, 7 (11): : 8096 - 8104
  • [27] Pivotal Advance:: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound
    Loiarro, Maria
    Capolunghi, Federica
    Fanto, Nicola
    Gallo, Grazia
    Campo, Silvia
    Arseni, Brunilde
    Carsetti, Rita
    Carminati, Paolo
    De Santis, Rita
    Ruggiero, Vito
    Sette, Claudio
    JOURNAL OF LEUKOCYTE BIOLOGY, 2007, 82 (04) : 801 - 810
  • [28] Accelerated hit identification with target evaluation, deep learning and automated labs: prospective validation in IRAK1
    Kamuntavicius, Gintautas
    Prat, Alvaro
    Paquet, Tanya
    Bastas, Orestis
    Aty, Hisham Abdel
    Sun, Qing
    Andersen, Carsten B.
    Harman, John
    Siladi, Marc E.
    Rines, Daniel R.
    Flatters, Sarah J. L.
    Tal, Roy
    Norvaisas, Povilas
    JOURNAL OF CHEMINFORMATICS, 2024, 16 (01):
  • [29] Double trouble: IRAK1/4 inhibitors in AML/MDS
    Uckelmann, Hannah J.
    Klusmann, Jan-Henning
    BLOOD, 2023, 142 (11) : 945 - 946
  • [30] PHARMACOLOGICAL INHIBITION OF IRAK1 AND IRAK4 PREVENTS ENDOTHELIAL INFLAMMATION AND ATHEROSCLEROSIS IN MICE
    Wu, X.
    Xu, M.
    Liu, Z.
    Zhang, Z.
    Liu, Y.
    Luo, S.
    Zheng, X.
    Xu, S.
    Weng, J.
    ATHEROSCLEROSIS, 2022, 355 : E91 - E91
12345